Adjuvant bisphosphonates in early breast cancer: Consensus guidance for clinical practice from a European Panel

Annals of Oncology

Volumn 27, Issue 3, 2016, Pages 379-390

  Hadji, P ^a   Coleman, Robert E ^b   Wilson, C ^b   Powles, T J ^c   Clezardin P ^d   Aapro, M ^e   Costa, L ^f   Body, J J ^g   Markopoulos, C ^h   Santini, D ⁱ   Diel, I ^j   Di Leo, A ^k   Cameron, D ^l   Dodwell, D ^m   Smith, I ⁿ   Gnant, M ^o   Gray, R ^p   Harbeck, N ^q   Thurlimann, B ^r   Untch, M ^s   Cortes, J ^t   Martin, M ^u   Albert, U S ^a   Conte, P F ^v   Ejlertsen, B ^w,x   Bergh, J ^y   Kaufmann, M ^z   Holen, I ^b   more..

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c Cancer Centre London   (United Kingdom)

^d UNIVERSITÉ LYON 1   (France)

^e Multidisciplinary Institute of Oncology   (Switzerland)

^f HOSPITAL DE SANTA MARIA   (Portugal)

^g BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

^h UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

ⁱ UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^j Institute for Gynecologic Oncology   (Germany)

^k Hospital of Prato   (Italy)

^l UNIVERSITY OF EDINBURGH   (United Kingdom)

^m ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

ⁿ INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^o MEDICAL UNIVERSITY OF VIENNA   (Austria)

^p UNIVERSITY OF OXFORD   (United Kingdom)

^q UNIVERSITY OF MUNICH   (Germany)

^r CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^s HELIOS KLINIKUM BERLIN BUCH   (Germany)

^t VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^u UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^v UNIVERSITY OF PADOVA   (Italy)

^w Danish Breast Cancer Cooperative Group   (Denmark)

^x University of Copenhagen   (Denmark)

^y KAROLINSKA INSTITUTE   (Sweden)

^z GOETHE UNIVERSITY   (Germany)

more..

Author keywords

Adjuvant; Bisphosphonates; Breast cancer; Guidelines

Indexed keywords

ALENDRONIC ACID; ANASTROZOLE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; ESTRADIOL; ESTROGEN; GOSERELIN; IBANDRONIC ACID; INHIBIN; LETROZOLE; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; TAMOXIFEN; VITAMIN D; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADVERSE DRUG REACTION; ANDROGEN DEPRIVATION THERAPY; BONE DENSITY; BONE METASTASIS; BONE SPECIALIST; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER TREATMENT INDUCED BONE LOSS; CLINICAL PRACTICE; CONSENSUS; DISEASE FREE SURVIVAL; DRUG ACTIVITY; DRUG POTENCY; EARLY CANCER; ESTRAOSSEOUS METASTASIS; EUROPEAN; EXTRAOSSEOUS METASTASIS; FRACTURE; HAZARD RATIO; HORMONE RELEASE; HUMAN; MEDICAL SPECIALIST; META ANALYSIS; METASTASIS; METASTASIS FREE SURVIVAL; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; OSTEOLYSIS; OVARIAN SUPPRESSION; OVARY FUNCTION; OVERALL SURVIVAL; PATIENT COMPLIANCE; POSTMENOPAUSE; PRACTICE GUIDELINE; PREMENOPAUSE; PRIORITY JOURNAL; QUESTIONNAIRE; RATING SCALE; RECURRENT DISEASE; RESISTANCE TRAINING; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; T SCORE; TREATMENT DURATION; BONE NEOPLASMS; BREAST NEOPLASMS; CHEMICALLY INDUCED; EUROPE; FEMALE; OSTEOPOROSIS; PREVENTION AND CONTROL; SECONDARY; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLODRONIC ACID; CONSENSUS; DIPHOSPHONATES; EUROPE; FEMALE; HUMANS; IMIDAZOLES; NEOPLASM RECURRENCE, LOCAL; OSTEOPOROSIS; SURVEYS AND QUESTIONNAIRES;

EID: 84959879550     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv617     Document Type: Review

References (81)

1. Coleman R, Body JJ, Aapro M, Hadji P, Herrstedt J. Bone health in cancer patients: ESMO clinical practice guidelines. Ann Oncol 2014; 25(Suppl 3): iii124-iii137.
2. Fink A, KosecoffJ, Chassin M, Brook RH. Consensus methods: characteristics and guidelines for use. Am J Public Health 1984; 74: 979-983.
3. Kanis JA, Oden A, Johnell O et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 2007; 18: 1033-1046.
4. Eastell R, Hannon R. Long-term effects of aromatase inhibitors on bone. J Steroid Biochem Mol Biol 2005; 95: 151-154.
5. Nicks KM, Fowler TW, Akel NS et al. Bone turnover across the menopause transition: the role of gonadal inhibins. Ann N Y Acad Sci 2010; 1192: 153-160.
6. Vehmanen L, Saarto T, Elomaa I et al. Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment. Eur J Cancer 2001; 37: 2373-2378.
7. Coleman RE, Rathbone E, Brown JE. Management of cancer treatment-induced bone loss. Nat Rev Rheumatol 2013; 9: 365-374.
8. Saarto T, Blomqvist C, Valimaki M et al. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol 1997; 15: 1341-1347.
9. Shapiro CL, Halabi S, Hars V et al. Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. Eur J Cancer 2011; 47: 683-689.
10. Powles TJ, McCloskey E, Paterson AH et al. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst 1998; 90: 704-708.
11. Delmas PD, Balena R, Confravreux E et al. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol 1997; 15: 955-962.
12. Sverrisdottir AFT, Jacobsson H. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. J Clin Oncol 2004; 22: 3694-3699.
13. Fogelman I, Blake GM, Blamey R et al. Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Osteoporos Int 2003; 14: 1001-1006.
14. Gnant M, Mlineritsch B, Luschin-Ebengreuth G et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year followup of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 2008; 9: 840-849.
15. Francis PA, Regan MM, Fleming GF et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 2015; 372: 436-446.
16. Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996; 14: 78-84.
17. Burstein HJ, Temin S, Anderson H et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American society of clinical oncology clinical practice guideline focused update. J Clin Oncol 2014; 32: 2255-2269.
18. Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005; 97: 1652-1662.
19. Goss PE, Hadji P, Subar M et al. Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women. Breast Cancer Res 2007; 9: R52.
20. Mouridsen H, Giobbie-Hurder A, Goldhirsch A et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 2009; 361: 766-776.
21. Cuzick J, Sestak I, Forbes JF et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet 2014; 383: 1041-1048.
22. Eastell R, Adams J, Clack G et al. Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial. Ann Oncol 2011; 22: 857-862.
23. Coleman RE, Banks LM, Girgis SI et al. Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study. Breast Cancer Res Treat 2010; 124: 153-161.
24. Reid DM, Doughty J, Eastell R et al. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev 2008; 34(Suppl 1): S3-18.
25. Hadji P, Aapro MS, Body JJ et al. Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Ann Oncol 2011; 22: 2546-2555.
26. Hadji P, Gnant M, Body JJ et al. Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention? Cancer Treat Rev 2012; 38: 798-806.
27. Peppone LJ, Mustian KM, Janelsins MC et al. Effects of a structured weightbearing exercise program on bone metabolism among breast cancer survivors: a feasibility trial. Clin Breast Cancer 2010; 10: 224-229.
28. Winters-Stone KM, Dobek J, Nail L et al. Strength training stops bone loss and builds muscle in postmenopausal breast cancer survivors: a randomized, controlled trial. Breast Cancer Res Treat 2011; 127: 447-456.
29. Waltman NL, Twiss JJ, Ott CD et al. The effect of weight training on bone mineral density and bone turnover in postmenopausal breast cancer survivors with bone loss: a 24-month randomized controlled trial. Osteoporos Int 2010; 21: 1361-1369.
30. Yin L, Grandi N, Raum E et al. Meta-analysis: serum vitamin D and breast cancer risk. Eur J Cancer 2010; 46: 2196-2205.
31. Silverman SL, Calderon AD. The utility and limitations of FRAX: a US perspective. Curr Osteoporos Rep 2010; 8: 192-197.
32. Hillner BE, Ingle JN, Chlebowski RT et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003; 21: 4042-4057.
33. Hershman DL, McMahon DJ, Crew KD et al. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol 2008; 26: 4739-4745.
34. Kim JE, Ahn JH, Jung KH et al. Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01). Breast Cancer Res Treat 2011; 125: 99-106.
35. Hines SL, Mincey BA, Sloan JA et al. Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer. J Clin Oncol 2009; 27: 1047-1053.
36. Lester JE, Dodwell D, Purohit OP et al. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 2008; 14: 6336-6342.
37. Van Poznak C, Hannon RA, Mackey JR et al. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol 2010; 28: 967-975.
38. Yamada KKN, Endoh K et al. The role of bisphosphonates and bone health issues in Japanese breast cancer patients: efficacy of alendronate with aromatase inhibitors. J Clin Oncol 2006; 24(suppl): abstr 10777.
39. Brufsky A, Harker WG, Beck JT et al. Zoledronic acid inhibits adjuvant letrozoleinduced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 2007; 25: 829-836.
40. Llombart A, Frassoldati A, Paija O et al. Immediate administration of zoledronic acid reduces aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trial. Clin Breast Cancer 2012; 12: 40-48.
41. Valachis A, Polyzos NP, Coleman RE et al. Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis. Oncologist 2013; 18: 353-361.
42. Gnant M, Pfeiler G, Dubsky PC et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2015; 386: 433-443.
43. Hadji P, Claus V, Ziller V et al. GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int 2012; 23: 223-231.
44. Wilson C, Coleman RE. Adjuvant therapy with bone-targeted agents. Curr Opin Support Palliat Care 2011; 5: 241-250.
45. Saad F, Brown JE, Van Poznak C et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 2012; 23: 1341-1347.
46. Migliorati CA, Epstein JB, Abt E, Berenson JR. Osteonecrosis of the jaw and bisphosphonates in cancer: a narrative review. Nat Rev Endocrinol 2011; 7: 34-42.
47. Daubine F, Le Gall C, Gasser J, Green J, Clezardin P. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst 2007; 99: 322-330.
48. Neudert M, Fischer C, Krempien B, Bauss F, Seibel MJ. Site-specific human breast cancer (MDA-MB-231) metastases in nude rats: model characterisation and in vivo effects of ibandronate on tumour growth. Int J Cancer 2003; 107: 468-477.
49. van der Pluijm G, Que I, Sijmons B et al. Interference with the microenvironmental support impairs the de novo formation of bone metastases in vivo. Cancer Res 2005; 65: 7682-7690.
50. Aft R, Naughton M, Trinkaus K et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol 2010; 11: 421-428.
51. Rack B, Juckstock J, Genss EM et al. Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer. Anticancer Res 2010; 30: 1807-1813.
52. Banys M, Solomayer EF, Gebauer G et al. Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial. BMC cancer 2013; 13: 480.
53. Hoffmann O, Aktas B, Goldnau C et al. Effect of ibandronate on disseminated tumor cells in the bone marrow of patients with primary breast cancer: a pilot study. Anticancer Res 2011; 31: 3623-3628.
54. Brown HKOP, Evans CE, Coleman RE, Holen I. A single administration of combination therapy inhibits breast tumour progression in bone and modifies both osteoblasts and osteoclasts. J Bone Oncol 2012; 1: 47-56.
55. Ottewell PD, Wang N, Brown HK et al. Zoledronic acid has differential antitumor activity in the pre-and postmenopausal bone microenvironment in vivo. Clin Cancer Res 2014; 20: 2922-2932.
56. Ottewell PD, Wang N, Meek J et al. Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone. Endocr Relatd cancer 2014; 21: 769-781.
57. Roelofs AJ, Thompson K, Gordon S, Rogers MJ. Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 2006; 12: 6222s-6230s.
58. Zheng Y, Zhou H, Brennan K et al. Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis. Bone 2007; 40: 471-478.
59. Buijs JT, Que I, Lowik CW, Papapoulos SE, van der Pluijm G. Inhibition of bone resorption and growth of breast cancer in the bone microenvironment. Bone 2009; 44: 380-386.
60. Holen I, Coleman RE. Anti-tumour activity of bisphosphonates in preclinical models of breast cancer. Breast Cancer Res 2010; 12: 214.
61. Diel IJ, Jaschke A, Solomayer EF et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol 2008; 19: 2007-2011.
62. Powles T, Paterson A, McCloskey E et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res 2006; 8: R13.
63. Saarto T, Vehmanen L, Virkkunen P, Blomqvist C. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol 2004; 43: 650-656.
64. Paterson AH, Anderson SJ, Lembersky BC et al. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol 2012; 13: 734-742.
65. von Minckwitz G, Mobus V, Schneeweiss A et al. German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer. J Clin Oncol 2013; 31: 3531-3539.
66. Kristensen B, Ejlertsen B, Mouridsen HT et al. Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncol 2008; 47: 740-746.
67. Coleman R, Cameron D, Dodwell D et al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. Lancet Oncol 2014; 15: 997-1006.
68. Gnant M, Mlineritsch B, Schippinger W et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009; 360: 679-691.
69. Gnant M, Mlineritsch B, Stoeger H et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Ann Oncol 2015; 26: 313-320.
70. Coleman RE, Marshall H, Cameron D et al. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 2011; 365: 1396-1405.
71. Bundred NJ, Campbell ID, Davidson N et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. Cancer 2008; 112: 1001-1010.
72. Coleman R, de Boer R, Eidtmann H et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol 2013; 24: 398-405.
73. Gregory WMH, Coleman RE et al. Adjuvant zoledronic acid (ZOL) in postmenopausal women with breast cancer and those rendered postmenopausal: results of a metaanalysis. J Clin Oncol 2012; 30(suppl): abstr 513.
74. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Coleman R, Powles T et al. Adjuvant bisphosphonate treatment in early breast cancer: metaanalyses of individual patient data from randomised trials. Lancet 2015; 386: 1353-1361.
75. Wilson C, Holen I, Coleman RE. Seed, soil and secreted hormones: potential interactions of breast cancer cells with their endocrine/paracrine microenvironment and implications for treatment with bisphosphonates. Cancer Treat Rev 2012; 38: 877-889.
76. WHO. WHO technical report series; 866. In: Organaiztion WH, ed. WHO Scientific Group on Research on the Menopause in the 1990s. Geneva; 1996.
77. Gralow JBW, Paterson AHG, Lew D et al. Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG-ACRIN/NCIC Clinical Trials Group/NRG Oncology study S0307: In: 2015 ASCO Annual Meeting; 2015; 33 (suppl): abstr 503.
78. Kremer R, Gagnon B, Meguerditchian AN, Nadeau L, Mayo N. Effect of oral bisphosphonates for osteoporosis on development of skeletal metastases in women with breast cancer: results from a pharmaco-epidemiological study. J Natl Cancer Inst 2014; 106: pii: dju264. doi: 10.1093/jnci/dju264.
79. Haider MT, Holen I, Dear TN, Hunter K, Brown HK. Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasis. Bone 2014; 66: 240-250.
80. Coscia M, Quaglino E, Lezzi M, Curcio C et al. Zoledronic acid repolarises tumour associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med 2010; 14: 2803-2815
81. Benzaid I, Monkkonen H, Stresing V, Clezardin P et al. High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo. Cancer Res 2011; 71: 4562-4572.